Tag Archives: treatment

The Benefits of Vitamin C in Cancer Treatment

In this interview, Dr. Nathan Goodyear discusses the benefits of vitamin C in cancer treatment. We are both scheduled speakers at the Vitamin C International Consortium Institute’s annual conference in Tampa, Florida, September 9 and 10, 2022. Goodyear started out as a gynecologist and pelvic floor surgeon. Once out of residency, however, he noticed that… Read More »

Acousia Therapeutics to present its first-in-class hearing loss treatment program with ACOU085 at the 2nd Inner Ear Therapeutics Summit in Boston

Tübingen, Germany, May 11, 2022 Acousia Therapeutics GmbH will be presenting data on the company’s clinical stage, first-in-class lead candidate ACOU085 at the Hanson Wade 2nd Inner Ear Therapeutics Summit to be held in person in Boston (MA) from June 20–23, 2022. ACOU085 is a proprietary, first-in-class, small-molecule otoprotective drug candidate, which is currently being… Read More »

Melatonin — A Standard of Treatment Adjunct for Acute Infections?

This article was previously published October 19, 2020, and has been updated with new information. According to a June 2020 research paper,1 melatonin2,3 may be an important adjunct to COVID-19 treatment. Incidentally, while not emphasized, melatonin is an optional addition to the highly effective MATH+ protocol promoted by the Front Line COVID-19 Critical Care Working… Read More »

FDA Approves Verkazia (cyclosporine ophthalmic emulsion) for the Treatment of Vernal Keratoconjunctivitis

FDA Approves Verkazia (cyclosporine ophthalmic emulsion) for the Treatment of Vernal Keratoconjunctivitis EMERYVILLE, Calif.–(BUSINESS WIRE) June 24, 2021 –Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on eye care, today announced that the U.S. Food and Drug Administration (FDA) has approved Verkazia (cyclosporine ophthalmic emulsion) 0.1%… Read More »

FDA Approves Lybalvi (olanzapine and samidorphan) for the Treatment of Schizophrenia and Bipolar I Disorder

FDA Approves Lybalvi (olanzapine and samidorphan) for the Treatment of Schizophrenia and Bipolar I Disorder DUBLIN, June 1, 2021 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved Lybalvi (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with… Read More »